TriangleIMSA101 (NCT06601296)
IMSA101 trial for Metastatic Renal Cell Carcinoma ( mRCC) (NCT06601296). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with metastatic clear-cell kidney cancer and up to five tumors progressing during or after checkpoint treatment. All must be suitable for radiation, and one for injection.
The idea: combine focused radiation, IMSA101 injected into one tumor, and monthly nivolumab. IMSA101 activates immune signaling; nivolumab blocks an immune brake. Researchers test whether this combination delays progression. A baseline biopsy is required.
This phase 2 study plans 15 patients. Raquibul Hannan leads at UT Southwestern in Dallas, the sole recruiting US location.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.